Infinity deep brain stimulation system approved in the USA

Infinity DBS System

St Jude Medical has announced the United States Food and Drug Administration approval and first implant of the Infinity deep brain stimulation (DBS) system and its DBS directional leads, the first directional lead approved in the United States. Combined with the first and only wireless iOS software platform available to DBS patients and physicians, the Infinity system provides a discreet, personalised experience for patients suffering from Parkinson’s disease or essential tremor, while delivering targeted relief of only the necessary areas.

The Infinity DBS system was first implanted by Kelly Foote, professor of neurosurgery and co-director of the University of Florida Center for Movement Disorders and Neurorestoration at the UF Health Shands Hospital, Gainesville, USA.

“I am very happy that the Infinity DBS system and its directional DBS lead are now available in the USA. I believe that the directional lead represents an important advancement in DBS technology that has the potential to improve outcomes of DBS therapy for many patients. This new system offers the potential to diminish adverse effects of DBS by steering current away from areas of the brain that cause side effects, allowing us to better control the symptoms of Parkinson’s disease and essential tremor,” says Foote.

The Infinity system is indicated to treat two of the most common movement disorders—Parkinson’s disease and essential tremor. Movement disorders are neurological conditions caused by a communication breakdown throughout the central nervous system that can result in a debilitating loss of muscle control, involuntary movement and reduced coordination. There are currently no proven cures for movement disorders, which means treatment options focus on alleviating symptoms to improve quality of life.

“The new Infinity DBS system is an advanced technology that has the potential to provide more choices to patients with Parkinson’s disease and essential tremor,” says Michael S Okun, chairman of the department of neurology at UF College of Medicine and the national medical director for the National Parkinson Foundation, USA. “The Infinity DBS system has a newly designed DBS lead with segmented contacts, which can be used to tailor the DBS therapy approach for an individual patient and to optimize benefits while reducing common DBS-related side effects.”

According to the company, the Infinity system also offers new, distinct patient advantages such as being the world’s first and only DBS system operating on a wireless iOS software platform. The system uses a clinician programmer with an iPad mini mobile digital device and an iPod touch mobile digital device patient controller with Bluetooth LE connectivity that can expedite the programming process for the neurologist, while offering patients a discreet experience. Conveniently, the system battery is available in two different sizes to accommodate different body types and offers a maintenance-free, long-lasting recharge-free option for DBS therapy.